Reduced cancer incidence has been reported among type II diabetics treated with metformin. Laboratory models have
demonstrated that metformin has anti-proliferative and anti-neoplastic effects associated with inhibition of mTORC1, but
the sequellae of this inhibition are poorly understood. Here we show that metformin regulates gene expression at the level of
mRNA translation, to an extent comparable to canonical mTOR inhibitors (rapamycin and PP242), and that its anti-proliferative
activity involves selective translational suppression of mRNAs encoding cell cycle regulators via the mTORC1/4E-BP pathway.
Thus metformin is a selective inhibitor of mRNA translation and thereby affects the proteome, suggesting applications in cancer
prevention and treatment.
Ola Larsson completed his Ph.D at Karolinska Institutet and, following postdoctoral studies at University of Minnesota and McGill University, is
currently an assistant professor at Karolinska Insitute Department of Oncology-Pathology. He has published more than 35 papers in reputed journals.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals